Tips from Other Journal

Chronic Corticosteroid Use in Patients with COPD



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2001 Jan 15;63(2):364.

The benefits of chronic corticosteroid use in patients with chronic obstructive pulmonary disease (COPD) are not well-established. Compared with patients who have asthma, patients with COPD have unclear benefits from corticosteroids. Nevertheless, many patients with COPD are labeled “steroid-dependent” and continue taking chronic doses of oral or inhaled corticosteroids. Few randomized trials have been conducted to determine the additional benefit of this therapy in patients with COPD. Rice and colleagues performed a double-blind, placebo-controlled trial of 38 patients with “steroid-dependent” COPD to determine the effect of withdrawing systemic corticosteroid therapy in patients on “maintenance” low-dose therapy.

Eligible subjects included those who met the American Thoracic Society criteria of COPD. All had been taking prednisone at a daily dosage of at least 5 mg per day for the preceding six months. Excluded were those with a clinical diagnosis of asthma, a strong family history of atopy or a concomitant major illness. All subjects also received inhaled triamcinolone acetonide. Patients were randomly assigned to receive their usual maintenance dose of prednisone for six months or to be withdrawn from prednisone at a rate of 5 mg per week.

Study results revealed that the number of COPD exacerbations per patient was similar (2.5 to 2.7). Spirometric results, dyspnea and health-related quality of life indicators did not differ significantly between the two groups. Weight decreased in the demand group by 4.8 kg, compared with a 0.5 kg increase in the continuous group.

The authors concluded that withdrawal of chronic low-dose systemic steroids did not adversely affect COPD–related outcomes. Furthermore, steroid-associated complications, such as weight gain, were affected by withdrawal of this agent.

Rice KL, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD. A randomized trial. Am J Respir Crit Care Med. July 2000;162:174–8.

editor's note: Family physicians caring for patients with COPD who are taking chronic low-dose systemic corticosteroids should consider the slow discontinuation of this medication and instead make use of demand dosing. It is likely that this change will not adversely affect the management of the disease. Furthermore, patients are likely to experience quality-of-life benefits from discontinuing oral corticosteroid therapy, including reduced body weight.—j.n.

 


Copyright © 2001 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article